Profile Response Detail

Molecular Profile Unknown unknown
Therapy Capecitabine + Oxaliplatin + Vandetanib
Indication/Tumor Type colorectal cancer
Response Type not applicable
Create By c-spatt
Update By smockus


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer not applicable Capecitabine + Oxaliplatin + Vandetanib Phase I Actionable In a Phase I clinical trial, the combination of Caprelsa (vandetanib), Xeloda (capecitabine), and Eloxatin (oxaliplatin) was well tolerated and demonstrated some efficacy in patients with colorectal cancer (PMID: 21404105). 21404105
PubMed Id Reference Title Details
(21404105) A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Full reference...